USCOM LIMITED — Regulatory Filings 2017

Nov 12, 2017

ASX MEDIA RELEASE

Uscom receives GSA listing to sell to US Government

• GSA listing required to sell into US Govt and Vet Affairs

• $45B US Federal Govt, Vet Affairs, and State and Local Govt market

• • Listing for USCOM 1A soon to be updated with BP+ and SpiroSonic

SYDNEY, Australia, Monday 13[th] November 2017: Uscom Limited (ASX code: UCM) (the Company or Uscom ) announced the receipt of USA General Services Administration Schedule (GSA) listing. The listing provides details of pricing and other terms and conditions of supply and is required to sell into the $45B USD PA Government market that includes the USA Federal Government, Veterans Affairs (VA), and some State and Local Governments.

GSA listing is available to businesses, non-profit organisations and educational Institutions to sell products and services to US Government customers, the largest purchaser of medical devices in the USA, which is the largest medical device market in the world.

The benefits of holding a GSA Schedule listing include:

1. Access to $45B USD annual market

2. Reduced pool of competition

3. Shorter simplified sales process

4. Competitive advantages in the Federal market

5. Can be used for all Federal Agencies

6. In some cases can be used for State and Local Government purchasers

The USCOM 1A is currently being loaded onto the GSA Advantage website, the Government shopping site. It has taken over 3 years to receive this listing and required prior FDA approval, the support of current clients, significant pre-existing US sales, product demand of a certain magnitude, and compliance with the application process prior to listing. As the BP+ and SpiroSonic devices receive FDA approval they too will be admitted under the current Uscom GSA listing.

The VA organisation, covered by the GSA listing, is the largest integrated health care system in the USA, providing care at 1,233 health care facilities, including 168 VA Medical Centers and 1,053 outpatient sites (VHA outpatient clinics), serving more than 8.9 million Veterans each year.

Executive Chairman of Uscom, Associate Professor Rob Phillips said “GSA listing is more important than FDA for revenue. FDA is the US regulatory permission to sell, while GSA listing effectively puts our products on the “supermarket shelves” of most US medical device buyers, and this is a real path to volume sales. Now every Government agency purchasing a cardiovascular monitor will have the USCOM 1A offered as a choice with a simplified purchase process. Our new GSA listing should also free up many of our pipeline sales awaiting approval. The application was a consequence of our USCOM 1A sale into the US Naval Base in San Diego, and a general increase in US USCOM 1A demand and enquiries. The GSA Advantage website provides internet marketing of our approved devices, and will be particularly effective for our BP+ and SpiroSonic products once they get FDA clearance.

Uscom have been cautious entering the US market because it’s expensive and is complex to access. The new GSA listing will simplify our US marketing strategy and provides a green light for our sales team in the US, accelerating current sales and greatly expanding new US sales opportunities.”

Reference: http://gsa.federalschedules.com/about/

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au